diost
ativus farmacÊutica ltda - progestagenos simples
dienogeste
germed farmaceutica ltda - dienogeste - progestagenos simples
dienogeste
nova quimica farmacÊutica s/a - dienogeste - progestagenos simples
alandre
legrand pharma indÚstria farmacÊutica ltda - dienogeste - progestagenos simples
dinorá
nova quimica farmacÊutica s/a - dienogeste - progestagenos simples
ludili ed
ems s/a - dienogeste - progestagenos simples
meluren
aché laboratórios farmacêuticos s.a - dienogeste - progestagenos simples
dienogeste
achÉ laboratÓrios farmacÊuticos s.a - dienogeste - progestagenos simples
acetato de ciproterona
laboratÓrio quÍmico farmacÊutico bergamo ltda - acetato de ciproterona - progestagenos simples
adcetris
takeda pharma a/s - brentuximab vedotin - lymphoma, non-hodgkin; hodgkin disease - agentes antineoplásicos - hodgkin lymphomaadcetris is indicated for adult patients with previously untreated cd30+ stage iv hodgkin lymphoma (hl) in combination with doxorubicin, vinblastine and dacarbazine (avd). adcetris is indicated for the treatment of adult patients with cd30+ hl at increased risk of relapse or progression following autologous stem cell transplant (asct). adcetris is indicated for the treatment of adult patients with relapsed or refractory cd30+ hodgkin lymphoma (hl):following asct, orfollowing at least two prior therapies when asct or multi-agent chemotherapy is not a treatment option. systemic anaplastic large cell lymphomaadcetris in combination with cyclophosphamide, doxorubicin and prednisone (chp) is indicated for adult patients with previously untreated systemic anaplastic large cell lymphoma (salcl). adcetris is indicated for the treatment of adult patients with relapsed or refractory salcl. cutaneous t cell lymphomaadcetris is indicated for the treatment of adult patients with cd30+ cutaneous t cell lymphoma (ctcl) after at least 1 prior systemic therapy.